Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
about
Regulation of Bim in Health and DiseaseRole of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia developmentAXL kinase as a novel target for cancer therapyThe DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer CellsMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyTargeting the TAM Receptors in LeukemiaA Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor ResistanceActivation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.Axl as a mediator of cellular growth and survivalInactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma.Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancermiR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML)Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.AXL is an oncotarget in human colorectal cancer.The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.Critical signal transduction pathways in CLL.The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.Gene of the month: Axl.Giving AXL the axe: targeting AXL in human malignancy.Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.Dual gene activation and knockout screen reveals directional dependencies in genetic networks.ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition.A dynamic N-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitorsModelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines
P2860
Q26781203-EED14C60-DB80-41FA-8C5E-49B77C75DC16Q26861674-960DBB2F-FC71-4E49-ADC2-908D822DF9A3Q26863442-8142C8A3-6365-4112-96A9-99EFDD36734BQ27313466-372C90A4-E6A2-44EF-9DEA-1121DCEC7FB4Q28070028-44238042-5ADA-45BA-88A9-3D6B2C9816B7Q28078654-51547D9C-6732-4C91-95D7-AF750294CAFEQ28553892-0BA32C9B-C603-46E4-9F3C-40635ABCFB92Q33891230-600DAE91-384C-4BC4-B805-934600D397BBQ34619118-151B0FAE-1748-43DC-9810-F72FA3AC36D2Q35125173-F76C1DE7-C21E-41F9-8717-0EC6AEEB581AQ35775881-10EA8F3C-EACA-4299-8D81-DE75062C22C9Q35832938-E27FC9F2-9DFB-4F19-A5C2-DD7F74F6708CQ35839805-62DF42B3-23CB-4254-A28A-5A7EA13B8BBDQ36021012-DD611E3F-F9F1-4228-8E61-5F80746F0A70Q36414168-E2A0C623-6E22-4124-933D-F3EBBD13D004Q36426519-AC1D5548-21CB-41AB-8F40-AD2C300C0A8AQ36557240-37524D6C-A2C6-432D-AB0C-F67A87FB889AQ36926106-312941CC-CB34-441E-BE04-3587F2CE6267Q37109841-715FB508-C3DE-4D5A-A15B-1F5CD048E3B9Q37571068-D93B1B0D-F9AF-4204-A0E8-9782C8F90A83Q38104686-AACAA682-F9CF-4406-9EB6-5A9213BB167AQ38214511-AE8F8CF8-3C20-4306-A416-45B044662A8AQ38743594-78805DE8-B896-4BB5-8458-166F3C7BD8D8Q38763966-239E20BD-7008-4EE0-B63D-81FCA7448270Q38772267-31049FD3-C411-4863-BC27-27E086637614Q38801345-F2DF976F-82E6-4970-BA92-FCD70869600FQ38850971-90E351F3-7EDC-452E-8D37-E18D6B5AD502Q38853220-7526667B-8CC9-472A-8328-09C9CA207781Q39157476-833BB5D3-3795-42EA-946F-2F37F2F1E33CQ42155234-197631CC-2E49-41FF-A2A3-325A5C3C0930Q47141265-42846691-4405-413D-9360-BC2B5B311E90Q48243283-4A56476C-7CA8-43D5-9F5D-3C67395E2613Q51763031-F5E39B0E-2714-4D6A-95B6-8CD4253F3190Q53509565-3C07E8E1-5E5A-4CC9-9196-AFACDBEA5C68Q53814929-FDA65029-E05E-4D5D-B2C7-A9FC3E250330Q57293800-A4A61799-3347-403F-BA30-FE27646412CDQ58582644-1616C9D0-C629-45FD-BAE2-9D8EF138F5C0
P2860
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@ast
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@en
type
label
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@ast
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@en
prefLabel
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@ast
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@en
P2093
P2860
P921
P356
P1433
P1476
Mechanisms of AXL overexpressi ...... hronic myeloid leukemia cells.
@en
P2093
Arnaud Jacquel
Fréderic Luciano
Guillaume Robert
Jill Patrice Cassuto
Maeva Dufies
Nathalie Belhacene
Patrick Auberger
Sophie Raynaud
Thomas Cluzeau
P2860
P304
P356
10.18632/ONCOTARGET.360
P407
P577
2011-11-01T00:00:00Z